Rare condition listed as possible side effect of COVID-19 injections — Action News Now

EU medicines watchdog warns of ‘very rare’ spinal cord inflammation possibly linked to AstraZeneca and J&J vaccines


The European Medicines Agency wants to put warning labels on Covid-19 vaccines made by AstraZeneca and Johnson & Johnson, saying they have a “reasonable likelihood” that they could cause the disease in rare cases Spinal cord inflammation.

After three days of meetings and discussions, EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) friday says it wants to include a warning “Very rare cases of transverse myelitis (TM) reported after vaccination” Jab with Vaxzevria and Janssen.It also adds the condition as “Adverse reactions of unknown frequency” to Vaccine Overview.


EMA describes TM as a rare neurological disorder characterized by “Inflammation on one or both sides of the spinal cord,” This can lead to weakness, tingling, numbness, pain — or loss of pain — and problems with bowel and bladder function in the arms or legs.

The recommendation comes after the PRAC reviewed the available information and scientific literature on reported cases globally and concluded that “A causal relationship between the two vaccines and transverse myelitis is at least a plausible possibility.” However, it said “the benefit-risk profile of the two vaccines remained unchanged.”


The warning is intended to “Raising awareness among healthcare professionals and vaccinated people.” Doctors have been told to be alert for signs and symptoms of TM, while urging recipients to “seek immediate medical attention” if they develop symptoms.


Last month, EMA officially recognized Janssen jabs are given as a booster for those 18 and older, at least two months after previous vaccinations.

The PRAC also revised the product information for AstraZeneca’s Vaxzevria to reflect that significantly fewer cases of thrombosis and thrombocytopenia (TTS) were recorded after the second injection compared to the first.

Use of AstraZeneca’s vaccine, developed in partnership with Oxford University, has been scaled back as “Very rare” Side effects, UK government statistics from last summer estimated about 14.9 jabs per million doses. A study published in December blamed a very specific problem on Vaxzevria’s adenovirus vector.